Jacobs Levy Equity Management Inc. Sells 244,740 Shares of GoodRx Holdings, Inc. $GDRX

Key Points

• Jacobs Levy Equity Management Inc. reduced its stake in GoodRx Holdings, Inc. by 23.1%, selling 244,740 shares and owning 816,721 shares worth $3.6 million at the end of the most recent reporting period.
• GoodRx reported $0.09 EPS for the latest quarter, missing estimates by $0.01, with a revenue of $203.07 million, slightly below projections.
• Hedge funds and institutional investors own 63.77% of GoodRx's stock, with notable acquisitions and stake increases from firms like Northern Trust Corp and BNP Paribas Financial Markets.

Jacobs Levy Equity Management Inc. trimmed its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 23.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 816,721 shares of the company's stock after selling 244,740 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.21% of GoodRx worth $3,602,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Northern Trust Corp increased its stake in shares of GoodRx by 13.5% in the fourth quarter. Northern Trust Corp now owns 421,810 shares of the company's stock valued at $1,961,000 after buying an additional 50,256 shares during the period. BNP Paribas Financial Markets acquired a new stake in GoodRx during the 4th quarter valued at approximately $183,000. Balyasny Asset Management L.P. acquired a new stake in GoodRx during the 4th quarter valued at approximately $870,000. Brevan Howard Capital Management LP bought a new position in GoodRx during the 4th quarter worth approximately $148,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of GoodRx in the 4th quarter worth approximately $708,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Stock Performance

Shares of GDRX opened at $4.13 on Wednesday. GoodRx Holdings, Inc. has a one year low of $3.31 and a one year high of $7.90. The company has a market cap of $1.43 billion, a PE ratio of 41.30, a P/E/G ratio of 1.79 and a beta of 1.23. The stock has a 50-day moving average of $4.47 and a 200-day moving average of $4.45. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The firm had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. During the same quarter in the previous year, the company posted $0.08 EPS. The firm's revenue was up 1.2% on a year-over-year basis. On average, equities research analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $4.05, for a total value of $64,864.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.17% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on GDRX. Raymond James Financial cut shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research report on Friday, August 8th. UBS Group decreased their price target on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $6.00 price objective on shares of GoodRx in a research report on Monday, August 11th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $5.80.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

Want to see what other hedge funds are holding GDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.